Vancouver’s Chinook Therapeutics has raised a $65 million Series A financing round to discover and develop precision medicines for kidney diseases.
Founding investor Versant Ventures led the round with participation by fellow founding investor Apple Tree Partners and new investor Samsara BioCapital.
The Series A proceeds will fund the advancement of several kidney disease programs into clinical trials by 2021.
“Kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments for patients often leading to dialysis, transplantation and high costs to healthcare systems,” said Eric Dobmeier, president and CEO of Chinook.
“Drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints. These dynamics combine to create very attractive opportunities for Chinook to develop a portfolio of precision medicines for kidney diseases.”
Chinook is applying its proprietary discovery platform, which leverages single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with novel mechanisms of action against key kidney disease pathways.
Chinook was incubated through Versant’s Inception Sciences discovery engine in Vancouver.
Leave a Reply